MBX Biosciences, Inc. reposted this
We are proud to announce that the first patient has been dosed in our Phase 2 AvailTM trial evaluating MBX 2109, our parathyroid hormone (PTH) peptide prodrug that is designed to be long-acting and is in development for the treatment of chronic #hypoparathyroidism (HP). Leveraging our proprietary Precision Endocrine PeptideTM (PEPTM) platform technology, MBX 2109 is designed to provide convenient, once-weekly administration and a continuous, infusion-like PTH exposure with lower daily peak-to-trough ratios than observed with daily PTH dosing regimens. With this milestone, we move forward in our mission to support those with #endocrine disorders in leading fuller and healthier lives. Learn more:https://lnkd.in/e3GJxF2w